Meningioma Clinical Trial
Official title:
Plasma Extracellular Vesicles in Meningioma Patients Following Radiotherapy as Liquid Biopsy
While surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenable to surgery. Biopsies are often omitted in light of potential postoperative neurological deficits, resulting in a lack of histological grading and (molecular) risk stratification. In this prospective explorative biomarker study, extracellular vesicles in the bloodstream will be investigated in patients with macroscopic meningiomas to identify a biomarker for molecular risk stratification and disease monitoring.
In total, 60 patients with meningiomas and an indication of radiotherapy (RT) and macroscopic tumor on the planning MRI will be enrolled. Blood samples will be obtained before the start, during, and after radiotherapy, as well as during clinical follow-up every 6 months. Extracellular vesicles will be isolated from the blood samples, quantified and correlated with the clinical treatment response or progression. Further, nanopore sequencing-based DNA methylation profiles of plasma EV-DNA will be generated for methylation-based meningioma classification. This study will explore the dynamic of plasma EVs in meningioma patients under/after radiotherapy, with the objective of identifying potential biomarkers of (early) tumor progression. DNA methylation profiling of plasma EVs in meningioma patients may enable molecular risk stratification, facilitating a molecularly-guided clinical management in meningioma patients in the future. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04081701 -
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
|
Phase 4 | |
| Recruiting |
NCT03631953 -
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
|
Phase 1 | |
| Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
| Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
| Withdrawn |
NCT00985036 -
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
|
N/A | |
| Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
| Completed |
NCT01811524 -
The Etiology and Progression of Brain Tumors
|
N/A | |
| Completed |
NCT03648034 -
Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality
|
N/A | |
| Recruiting |
NCT06036706 -
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
|
N/A | |
| Recruiting |
NCT06014905 -
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
|
Phase 1 | |
| Not yet recruiting |
NCT04386642 -
Tranexamic Acid Reduce Blood Loss in Meningioma Resection
|
Phase 4 | |
| Active, not recruiting |
NCT04595786 -
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
|
N/A | |
| Active, not recruiting |
NCT04305470 -
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
|
Phase 3 | |
| Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02978677 -
Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas
|
N/A | |
| Active, not recruiting |
NCT02933736 -
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
|
Early Phase 1 | |
| Completed |
NCT02267928 -
Information Presentation Formats
|
N/A | |
| Completed |
NCT00589784 -
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
|
Phase 2 | |
| Active, not recruiting |
NCT03071874 -
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
|
Phase 2 | |
| Recruiting |
NCT05416567 -
Embolization for Meningioma
|
N/A |